复方天仙胶囊联合FOLFOX4双周标准化疗方案治疗中晚期胃癌的临床研究  

Clinical Study of Compound Tianxian Capsule Combined with FOLFOX4 Two-week Standard Chemotherapy Regimen in Treatment of Advanced Gastric Cancer

作　　者：龚瑜[1] 牛刚[2] 郑芝欣[1] 李敏[1] 王耿泽[2] 宋展[2] GONG Yu;NIU Gang;ZHENG Zhi-xin;LI Min;WANG Geng-ze;SONG Zhan(Department of Pharmacy,Nanyang Central Hospital,Nanyang 473000,China;Department of General Surgery,Nanyang Central Hospital,Nanyang 473000,China)

机构地区：[1]南阳市中心医院药学部,南阳473000 [2]南阳市中心医院普通外科,南阳473000

出　　处：《中国合理用药探索》2021年第11期81-85,共5页Chinese Journal of Rational Drug Use

摘　　要：目的:探讨复方天仙胶囊联合FOLFOX4双周标准化疗方案治疗中晚期胃癌患者的临床疗效。方法:选择2018年6月~2019年6月于本院首次住院治疗的98例中晚期胃癌患者作为研究对象,按照随机数字表法将其分为对照组和观察组,各49例。对照组采用FOLFOX4双周标准化疗方案进行治疗,观察组在对照组基础上口服复方天仙胶囊。比较两组临床疗效和不良反应发生率,采用卡氏功能状态评分(KPS)和视觉模拟评分(VAS)评估两组患者的生活质量和疼痛程度,并检测治疗前和治疗后血清白介素-6(IL-6)、白介素-17(IL-17)和白介素-33(IL-33)表达水平。结果:观察组总有效率(57.14%)高于对照组(32.65%,P<0.05)。观察组生活质量改善率(69.39%)高于对照组(44.90%,P<0.05)。治疗后,两组VAS评分低于治疗前,且观察组低于对照组(P<0.05)。治疗后,两组血清IL-6、IL-17、IL-33表达水平低于治疗前,且观察组低于对照组(P<0.05)。治疗期间,两组肝肾功能损伤、周围神经毒性及口腔黏膜炎等不良反应发生率比较无统计学差异(P>0.05),观察组恶心、呕吐和骨髓抑制发生率低于对照组(P<0.05)。结论:复方天仙胶囊联合FOLFOX4双周标准化疗方案治疗中晚期胃癌,可以提高临床疗效,改善患者生活质量,降低疼痛程度和血清炎症因子水平,且安全性较高,具有良好的临床应用价值。Objective:To explore the clinical efficacy of compound Tianxian capsule combined with FOLFOX4 two-week standard chemotherapy regimen in treatment of patients with advanced gastric cancer.Methods:A total of 98 patients with advanced gastric cancer first hospitalization and treatment in our hospital between June 2018 and June 2019 were selected as research subjects.All patients were divided into control group and observation group according to random number table,with 49 cases in each group.The control group was treated with FOLFOX4 two-week standard chemotherapy regimen,and the observation group was treated with compound Tianxian capsule on the basis of the control group.The clinical efficacy and incidence of adverse reactions were compared between the two groups.The life quality and pain degree of the two groups was evaluated by Karnofsky functional status score(KPS)and visual analogue scale(VAS),respectively.The expression levels of serum interleukin-6(IL-6),interleukin-17(IL-17)and interleukin-33(IL-33)were measured before and after treatment.Results:The total effective rate in the observation group(57.14%)was higher than the control group(32.65%,P<0.05).The improvement rate of life quality in the observation group(69.39%)was higher than that in the control group(44.90%,P<0.05).After treatment,the VAS score in the two groups was lower than that before treatment,and the observation group was lower than control group(P<0.05).After treatment,the expression levels of serum IL-6,IL-17 and IL-33 in the two groups were lower than those before treatment,and the observation group was lower than the control group(P<0.05).During treatment,there was no significant difference in the incidence of adverse reactions such as liver and kidney function injury,peripheral neurotoxicity and oral mucositis between the two groups(P>0.05).The incidence of nausea,vomiting and marrow suppression in the observation group were lower than those in the control group(P<0.05).Conclusion:Compound Tianxian capsule combined with FOLFOX4 two-week

关 键 词：复方天仙胶囊 中晚期胃癌 炎症因子 生活质量 临床疗效 不良反应 

分 类 号：R979.1[医药卫生—药品]